Fré Bauters

Fré Bauters

Auto-generated profile, based on publicly available information

Fré Bauters

Ghent University Hospital, Department of Respiratory Medicine, Ghent, Belgium

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2015 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
FBFré Bauters
Fré Bauters
ERErnst R. Rietzschel
Ernst R. Rietzschel
KHKatrien B. C. Hertegonne
Katrien B. C. Hertegonne
JCJulio A. Chirinos
Julio A. Chirinos

1 March 2020 in Sleep Medicine
Verified
Journal Article
Closed access
FBFré A. Bauters
Fré A. Bauters
SLSarah Loof
Sarah Loof
KHKatrien B. Hertegonne
Katrien B. Hertegonne
JCJulio A. Chirinos
Julio A. Chirinos
MBMarc L De Buyzere
Marc L De Buyzere
ERErnst R. Rietzschel
Ernst R. Rietzschel


2 September 2011 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Closed access
PDF file
MCMathieu Coeman
Mathieu Coeman
YDYannick van Durme
Yannick van Durme
FBFre Bauters
Fre Bauters
EDEllen Deschepper
Ellen Deschepper
IDIngel Demedts
Ingel Demedts
GBGuy Brusselle
Guy Brusselle
Rationale: Previous studies have demonstrated that long-term low-dose macrolides are efficacious in cystic fibrosis (CF) and diffuse panbronchiolitis, two chronic neutrophilic airway diseases. Aims: The aims of this study were to evaluate the efficacy and safety of low-dose neomacrolides as add-on therapy in patients with severe asthma and/or bronchiectasis and to identify predictors for therapeutic response. Methods: In a retrospective observational cohort study, we examined 131 adult, non-CF patients with severe asthma and/or bronchiectasis, receiving low-dose neomacrolides as add-on treatment. Pulmonary function tests and symptom scores were assessed at baseline and after 3 to 8 weeks of therapy. Results: After 3–8 weeks of treatment with low-dose neomacrolides, 108 patients were available for evaluation. In asthma patients ( n = 47), pulmonary function tests and symptom scores improved significantly. Responders (≥7% forced expiratory volume in one second predicted [FEV1%] improvement) were older (55 vs. 47 years; p = 0.042) and had a longer duration of asthma (29 vs. 9 years; p = 0.052). In patients with bronchiectasis only ( n = 61), symptom scores improved significantly. Responders (≥60% symptom score improvement) were older (61 vs. 53 years; p = 0.004), more frequently male (53% vs. 27%; p = 0.043), and there was a nonsignificant trend towards higher high-resolution CT (HRCT) score for bronchiectasis in responders (6.4 vs. 4.6; p = 0.053). In multivariate logistic regression analysis, age and male gender were independent predictors for improvement in this group. Conclusion: The results of this retrospective study suggest that neomacrolides may be useful as an add-on therapy in patients with severe asthma and/or bronchiectasis. Older age may predict good response in patients with severe asthma, whereas older age, male gender and a higher HRCT score for bronchiectasis may predict therapeutic response in patients with bronchiectasis only. Prospective controlled trials of neomacrolides in patients with severe asthma are needed to confirm these observations.

27 June 2019 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
LMLaura Muiño Mosquera
Laura Muiño Mosquera
FBFré Bauters
Fré Bauters
KDKarlien Dhondt
Karlien Dhondt
HWHans De Wilde
Hans De Wilde
LJLuc J.L.M. Jordaens
Luc J.L.M. Jordaens
JBJulie De Backer
Julie De Backer
Background: Marfan syndrome (MFS) is an inherited connective tissue disorder characterized by ectopia lentis, aortic root dilation and dissection and specific skeletal features. Obstructive sleep apnea (OSA) in MFS has been described earlier but the prevalence and its relation with the cardiovascular risk is still controversial. This study aimed to further investigate these aspects.Methods: In this prospective longitudinal study, we performed an attended polysomnography in 40 MFS patients (60% women, 37 ± 12.8 years) and evaluated several cardiovascular parameters through echocardiography, resting electrocardiogram, 24 hr‐Holter monitoring and serum NT‐ProBNP measurements.Results: We found that OSA was present in 42.5% of the patients and that higher body mass index was the most important factor associated with the presence of OSA. We observed that overweight was present in 27.5% of the patients in the whole cohort and in 55.6% if >40 years. Furthermore, when evaluating the impact of OSA on the cardiovascular system, we observed that patients with OSA tended to have higher systolic blood pressure, larger distal aortic diameters and a higher prevalence of ventricular arrhythmia. These differences were, however, not significant after adjusting for confounders.Conclusions: Our study shows a high prevalence of OSA and a high prevalence of overweight in MFS patients. We found some trends between OSA and cardiovascular features but we could not establish a solid association. Our study, however might be underpowered, and a multicenter collaborative study could be very useful to answer some important open questions.

1 May 2021 in Journal of Clinical Sleep Medicine
Verified
Journal Article
Closed access
FBFré A. Bauters
Fré A. Bauters
KHKatrien B. Hertegonne
Katrien B. Hertegonne
DPDirk Pevernagie
Dirk Pevernagie
MBMsc Marc L. De Buyzere
Msc Marc L. De Buyzere
JCJulio A. Chirinos
Julio A. Chirinos
ERErnst R. Rietzschel
Ernst R. Rietzschel
Study Objectives:To assess sex-related differences in the relationship between hypertension (HT), blood pressure (BP) and sleep apnea (SA) in the general population.Methods:We performed home polygr...